Remove 2023 Remove Cell Based Assays Remove Drug Development Remove Research
article thumbnail

Altasciences Completes Expansion of New State-Of-The-Art Laboratory in Columbia, Missouri

Alta Sciences

Altasciences Completes Expansion of New State-Of-The-Art Laboratory in Columbia, Missouri pmjackson Tue, 10/31/2023 - 16:08 Laval, Québec, October 31, 2023 – Altasciences is pleased to announce the completion of its laboratory facilities in Columbia, MO. This is Altasciences’ third purpose-built laboratory.

article thumbnail

Reflecting on ELRIG’s Drug Discovery 2022 

Drug Discovery World

Meanwhile, Stratech Bio were on hand to answer enquiries about their range of raw materials, kits and assays for R&D or bioprocessing projects. Not to mention, the 2023 calendar which, if the year-on-year trajectory continues in the same way as Drug Discovery 2022, should be a landmark year for drug discovery. .

Drugs 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Separating the Hype from the Hyperbole Surrounding FDORA’s Alternatives to Animal Testing under the FD&C Act

FDA Law Blog: Drug Discovery

While this hype may be warranted in some respects—a 60-year old legal provision has now been amended to acknowledge that the science of drug development is advancing—the change is mostly symbolic and is likely to take many years before we see it have a measurable impact. FDORA § 3209(a)(2).

article thumbnail

Article FDA Thank You Draft guidance on potency assays for CGT products garners extensive stakeholder input

Agency IQ

For example, in describing how potency should be demonstrated for CGT products, the 2011 guidance simply stated that potency for gene therapy products is derived from “at least two biological activities for its potency: the ability to transfer a genetic sequence to a cell; and the biological effect of the expressed genetic sequence.”

article thumbnail

AI At The Frontier: Empowering Early Career Professionals In Drug Discovery

Elrig

Miguel Gancedo Rodrigo Miguel Gancedo Rodrigo Research Investigator, Isomorphic Labs My name is Miguel, and I’m from Murcia, Spain. Driven by an interest in structural biochemistry and drug discovery (DD), I joined AstraZeneca in 2019. As a Research Investigator, I lead the biology domain of Iso’s DD programs.

article thumbnail

Re-assessing the risks of drug-induced arrhythmias during drug discovery

Drug Discovery World

Although such electrophysiological systems may be more predictive of potential cardiac safety and efficacy than non-functional binding assays, many apparently attractive new drugs are still being discontinued later in development. Unexpected late-stage failures in drug development are, of course, the costliest.

Drugs 130